Cargando…

Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints

BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jiaying, Ma, Xiaoxi, Zhang, Huiwei, Xiao, Zhenxu, Li, Ming, Wu, Jie, Ju, Zizhao, Chen, Li, Zheng, Li, Ge, Jingjie, Liang, Xiaoniu, Bao, Weiqi, Wu, Ping, Ding, Ding, Yen, Tzu-Chen, Guan, Yihui, Zuo, Chuantao, Zhao, Qianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308642/
https://www.ncbi.nlm.nih.gov/pubmed/37381042
http://dx.doi.org/10.1186/s40035-023-00365-x
Descripción
Sumario:BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. METHODS: A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging ((18)F-florbetapir for A, (18)F-Florzolotau for T, and (18)F-fluorodeoxyglucose [(18)F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. RESULTS: Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ− subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism – along with elevated plasma neurofilament light chain level – was related to more severe cognitive impairment in Aβ− subjects. CONCLUSION: Plasma p-tau181, as well as (18)F-florbetapir and (18)F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. (18)F-Florzolotau and (18)F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00365-x.